GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

Thrombosis Research InstituteAug 20 2015

-- A satellite symposium and four GARFIELD-AF presentations will demonstrate how antithrombotic treatment patterns are evolving in the real-world and the impact on clinical outcomes in newly diagnosed AF patients --

New analyses from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) will be presented at ESC Congress 2015 to be held in London, United Kingdom, from August 29 to September 2, 2015. Real-world insights into current therapy choices for patients with newly diagnosed AF will provide physicians with a better understanding of how the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) is impacting care and clinical outcomes generally as well as within distinctive populations.

Real-world data from over 40,000 patients will be presented at a satellite symposium, and at one platform and three poster presentations:

Anticoagulation and atrial fibrillation (AF): real life data from the GARFIELD-AF Registry

• Satellite Symposium: Sponsored by the Thrombosis Research Institute (TRI)
• Saturday, 29^th August 2015, 15:30-17:00, Madrid - Village 4

An expert faculty will discuss the design of GARFIELD-AF in the context of the value that registries bring to clinical research. They will also present the latest data on treatment and outcomes in the global population and in specific patient subgroups.

Vitamin K antagonist control in Eastern and Southeastern Asia (3278)

• Oral session: Thrombosis and coagulation: advances in science
• Monday 31^st August, 2015, 11:37, Tunis - Village 7

A comparison of the distribution of international normalized ratio (INR) values in patients receiving a vitamin K antagonist (VKA) for newly diagnosed AF in countries in Eastern and Southeastern Asia with that for patients in other countries represented in GARFIELD-AF.

Patterns of uptake of non-vitamin K antagonist oral anticoagulants in Europe: an analysis from the GARFIELD-AF registry (P1513)

• Poster session 2: Miscellaneous
• Sunday 30^th August 2015, 08:30-12:30, poster area

A comparison of temporal changes in NOACs uptake in patients with newly diagnosed AF in nine European countries.

Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF (P4404)

• Poster session 5: Atrial fibrillation and anticoagulation
• Monday 31^st August, 2015, 14:00-18:00, poster area

Evolving patterns of antithrombotic therapy in patients with newly diagnosed AF analysed by baseline characteristics and risk scores for stroke and major bleeding.

Stroke, major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe chronic kidney disease: results from GARFIELD-AF (P5598)

• Poster session 6: Stroke
• Tuesday 1^st September 2015, 08:30-12:00, poster area

A comparison of outcomes following real-world anticoagulant treatment in patients with AF and moderate-to-severe chronic kidney disease (CKD) versus those with AF and no/mild CKD.

These presentations will enhance the breadth and depth of the understanding of the importance of stroke prevention in AF, and ultimately will help to develop strategies for improving patient outcomes worldwide. Baseline data for more than 40,000 patients indicates that, currently, the management of many newly diagnosed patients is not consistent with evidence-based guidelines, with patients inappropriately receiving anticoagulants or being under-treated with anticoagulants, despite the increasing availability of NOACs. The impact of sub-optimal management strategies on patient outcomes suggests a cause for ongoing concern.